Holen Sie sich die Stockscreener-App
3.67
1.38%
0.05
Handel nachbörslich:
3.65
-0.02
-0.54%
Schlusskurs vom Vortag:
$3.62
Offen:
$3.69
24-Stunden-Volumen:
603.28K
Relative Volume:
0.34
Marktkapitalisierung:
$97.27M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.26M
KGV:
-1.799
EPS:
-2.04
Netto-Cashflow:
$-24.69M
1W Leistung:
-3.17%
1M Leistung:
+8.90%
6M Leistung:
+35.93%
1J Leistung:
-22.08%
1-Tages-Spanne:
$3.65
$3.86
1-Wochen-Bereich:
$3.5827
$4.2399
52-Wochen-Spanne:
$1.11
$5.60
Annovis Bio Inc Stock (ANVS) Company Profile
Firmenname
Annovis Bio Inc
Sektor
Branche
Telefon
484-875-3192
Adresse
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Vergleichen Sie ANVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
3.67 | 95.94M | 0 | -30.26M | -24.69M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-10 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2024-10-25 | Hochstufung | Maxim Group | Hold → Buy |
| 2023-12-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-07 | Bestätigt | Maxim Group | Buy |
Annovis Bio Inc Aktie (ANVS) Neueste Nachrichten
Annovis Bio to launch long-term Parkinson’s drug study in January - Investing.com India
Annovis Bio to launch long-term Parkinson’s drug study in January By Investing.com - Investing.com South Africa
Annovis Bio to Launch Long-Term Open-Label Study for Buntanetap in Parkinson's Disease Patients Starting January 2026 - Quiver Quantitative
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients - GlobeNewswire
Annovis Bio Advances Long-Term Buntanetap Safety Study in Parkinson’s Disease - TipRanks
Will Annovis Bio Inc. stock attract ESG investorsTrade Performance Summary & Real-Time Stock Entry Alerts - Улправда
Annovis to Host Corporate Update Webinar on January 28, 2026 - GlobeNewswire
Alzheimer's drug hunt learns from cancer fight's multi-target playbook - Reuters
Parkinson’s Breakthrough? New Data Shows Drug May Reverse Cognitive Decline - MSN
Keeping Neurodegeneration Top Of Mind: Is Annovis Bio's Pipeline Progress Enough? - RTTNews
ANVS SEC FilingsAnnovis Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Annovis Bio director Hoffman buys $193,794 in shares By Investing.com - Investing.com UK
Annovis Bio (NYSE:ANVS) Director Purchases $193,950.00 in Stock - MarketBeat
Annovis Bio (ANVS) director reports 45,000-share insider purchase at around $4 - Stock Titan
Annovis Bio director Hoffman buys $193,794 in shares - Investing.com
Chmn Hoffman Buys 45,000 ($193.8K) Of Annovis Bio Inc [ANVS] - TradingView — Track All Markets
Published on: 2025-12-08 04:36:17 - moha.gov.vn
Annovis Bio Inc. (ANVS) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Can Annovis Bio Inc. stock deliver consistent EPS growth2025 Retail Activity & High Yield Stock Recommendations - Newser
Is Annovis Bio Inc. stock a top hedge fund pickEarnings Beat & High Conviction Buy Zone Picks - Newser
Why institutional investors increase stakes in Annovis Bio Inc. stockEarnings Performance Report & Capital Efficiency Focused Ideas - Newser
Why Annovis Bio Inc. stock fits value portfoliosJuly 2025 Summary & Low Risk High Reward Ideas - Newser
Why Annovis Bio Inc. stock is a must watch tickerEarnings Risk Report & Weekly Watchlist for Consistent Profits - Newser
Annovis Bio (ANVS) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
How Annovis Bio Inc. stock compares with top peers2025 Price Targets & Weekly Stock Breakout Alerts - Newser
How geopolitical risks impact Annovis Bio Inc. stockWeekly Trade Recap & Weekly Return Optimization Alerts - Newser
Annovis Bio (ANVS) Stock Analysis Report | Financials & Insights - Benzinga
Annovis Bio to Present Comprehensive Buntanetap Data at Parkinson Study Group Meeting - citybuzz
Who are in the management team of Annovis Bio, Inc.? - Markets Mojo
Annovis Bio, Inc. to Present At the 2025 Annual Meeting of the Parkinson Study Group - marketscreener.com
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group - The Manila Times
Annovis Rallies Around Phase 3 Alzheimer’s Push as New Data Signals Disease-Modifying Promise - MSN
Annovis Bio, Inc. (NYSE:ANVS) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Certain Stock Options of Annovis Bio, Inc. are subject to a Lock-Up Agreement Ending on 30-NOV-2025. - marketscreener.com
Certain Warrants of Annovis Bio, Inc. are subject to a Lock-Up Agreement Ending on 30-NOV-2025. - MarketScreener
Why analysts remain bullish on Annovis Bio Inc. stock2025 Earnings Impact & Daily Profit Focused Stock Screening - moha.gov.vn
Michael Hoffman Acquires 39,200 Shares of Annovis Bio (NYSE:ANVS) Stock - MarketBeat
Annovis Bio : Amendment to Statement of Changes in Beneficial Ownership (Form 4/A) - marketscreener.com
Annovis Bio director Hoffman buys $159k in shares By Investing.com - Investing.com Nigeria
Alzheimer's Disease Market to Evolve Rapidly Over the Next - openPR.com
Annovis Bio director Hoffman buys $159k in shares - Investing.com
Annovis Bio Director Michael B Hoffman Buys 39,200 Shares - TradingView
Annovis Announces Two Presentations at the CTAD 2025 Conference - The Manila Times
Finanzdaten der Annovis Bio Inc-Aktie (ANVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.31%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):